Cargando…

Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity

[Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Kamal, Vartak, Abhishek, Sucheck, Steven J., Wall, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441943/
https://www.ncbi.nlm.nih.gov/pubmed/30949616
http://dx.doi.org/10.1021/acsomega.9b00029
_version_ 1783407628933660672
author Hossain, Md Kamal
Vartak, Abhishek
Sucheck, Steven J.
Wall, Katherine A.
author_facet Hossain, Md Kamal
Vartak, Abhishek
Sucheck, Steven J.
Wall, Katherine A.
author_sort Hossain, Md Kamal
collection PubMed
description [Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibody (anti-Rha), the bacterial sugar rhamnose conjugated with liposomal cancer antigen MUC1-Tn enhances antigen presentation by APCs such as dendritic cells by targeting Fc gamma receptors. The idea was to utilize the natural human anti-Rha antibodies present in human serum for targeted delivery of cancer-specific antigens. Recently, we found that the IgG3 antibody isotype was the most prevalent anti-Rha antibody generated in mice immunized with rhamnose-Ficoll (Rha-Ficoll) antigen. In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone. This Fc approach enhanced antibody production and T-cell proliferation almost to the same level as using the anti-Rha antibody. These results suggest that targeting Fc directly to dendritic cells can be an alternative approach to human anti-Rha for generating effective antigen-primed T-cells.
format Online
Article
Text
id pubmed-6441943
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-64419432019-04-02 Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity Hossain, Md Kamal Vartak, Abhishek Sucheck, Steven J. Wall, Katherine A. ACS Omega [Image: see text] Targeted delivery of antigens to antigen-presenting cells (APCs) by utilizing natural anticarbohydrate antibodies is a promising approach for selective uptake and enhanced antigen presentation. Previously, we reported that in the presence of a natural antibody, anti-rhamnose antibody (anti-Rha), the bacterial sugar rhamnose conjugated with liposomal cancer antigen MUC1-Tn enhances antigen presentation by APCs such as dendritic cells by targeting Fc gamma receptors. The idea was to utilize the natural human anti-Rha antibodies present in human serum for targeted delivery of cancer-specific antigens. Recently, we found that the IgG3 antibody isotype was the most prevalent anti-Rha antibody generated in mice immunized with rhamnose-Ficoll (Rha-Ficoll) antigen. In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone. This Fc approach enhanced antibody production and T-cell proliferation almost to the same level as using the anti-Rha antibody. These results suggest that targeting Fc directly to dendritic cells can be an alternative approach to human anti-Rha for generating effective antigen-primed T-cells. American Chemical Society 2019-03-13 /pmc/articles/PMC6441943/ /pubmed/30949616 http://dx.doi.org/10.1021/acsomega.9b00029 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Hossain, Md Kamal
Vartak, Abhishek
Sucheck, Steven J.
Wall, Katherine A.
Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title_full Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title_fullStr Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title_full_unstemmed Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title_short Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity
title_sort liposomal fc domain conjugated to a cancer vaccine enhances both humoral and cellular immunity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441943/
https://www.ncbi.nlm.nih.gov/pubmed/30949616
http://dx.doi.org/10.1021/acsomega.9b00029
work_keys_str_mv AT hossainmdkamal liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity
AT vartakabhishek liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity
AT sucheckstevenj liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity
AT wallkatherinea liposomalfcdomainconjugatedtoacancervaccineenhancesbothhumoralandcellularimmunity